Clinical trial · no report yet · Phase 3
ABC06
Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers
- NCT01926236 ↗
- Completed
- The Christie NHS Foundation Trust
- 39 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 15 | |
| X threads | 14 | |
| Podcasts | 10 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy.
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Biliary Tract Cancer; Gallbladder Cancer; Cholangiocarcinoma; Ampullary Cancer
- Interventions
- Active Symptom Control; L-folinic acid; 5 FU; Oxaliplatin
- Arms
- Arm A: Active symptom control (ASC) · Active comparator
- Arm B: ASC with OxMdG chemotherapy · Experimental
- Enrollment
- 162
- Primary outcomes
- Overall survival
- Sponsor
- The Christie NHS Foundation Trust with Cancer Research UK
- Start
- Feb 2014
- Primary completion
- Jan 5, 2018
- Results posted
- No
- Registry record
- NCT01926236 · updated Jan 28, 2020
Publications
linked from the registry- Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K, Anthoney A, Maraveyas A, Iveson T, Waters JS, Hobbs C, Barber S, Ryder WD, Ramage J, Davies LM, Bridgewater JA, Valle JW; Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021 May;22(5):690-701. doi: 10.1016/S1470-2045(21)00027-9. Epub 2021 Mar 30. PubMed 33798493